Azetukalner
Phase 3
Kv7 potassium channel opener listed at Phase 3 for focal onset seizures, bipolar depression, major depressive disorder and generalized seizures.
Learn more
Xenon Pharmaceuticals
Biotechnology & Life SciencesNasdaq: XENEBurnaby, BC
Burnaby-based neuroscience-focused biopharmaceutical company discovering and developing ion-channel-modulating therapeutics for neurological and psychiatric disorders.
Canadian innovation builds a brighter tomorrow.
About
Source: xenon-pharma.comXenon Pharmaceuticals describes itself as a neuroscience-focused biopharmaceutical company dedicated to delivering life-changing therapeutics for people in need. Founded in 1996 with a focus on discovering new genetic targets to treat human disease, it develops ion-channel-modulating therapeutics for neurological and psychiatric disorders.
Its X-TOLE2 study of azetukalner in focal onset seizures completed enrollment with 380 patients, with a topline readout anticipated in the first half of 2026. sec.gov
NBI-921355, partnered with Neurocrine, advanced into a Phase 1 study in February 2025, triggering a $7.5M milestone payment to Xenon. sec.gov
Initiated two Phase 1 studies in 2025 for pain candidates XEN1701 (Nav1.7) and XEN1120 (Kv7), with completion expected in 2026. sec.gov
States it was founded in 1996 with a focus on discovering new genetic targets to treat human disease. xenon-pharma.com
Products & Services
Company site: xenon-pharma.comProducts Xenon Pharmaceuticals publishes on its own site. Each card links to the page it was taken from.
XEN1701
Phase 1
Nav1.7 sodium channel programme for pain, listed at Phase 1.
Learn moreXEN1120
Phase 1
Kv7 programme for pain, listed at Phase 1.
Learn morePartnerships
Publicly announced partnerships.
Neurocrine Biosciences
NBI-921355 advanced into a Phase 1 study in February 2025 under the Neurocrine collaboration, triggering a $7.5M milestone payment to Xenon.
People
Sourced from the company's own pages or announcements.
Ian Mortimer
President and Chief Executive Officer
Tucker Kelly
Chief Financial Officer
Chris Kenney
Chief Medical Officer
Matthew D. Ronsheim
Chief Operating Officer
Technology Focus
Company site: xenon-pharma.comTerms the company uses about its own work.
Ion channel modulationKv7 potassium channelNav1.7 sodium channelEpilepsy therapeuticsPsychiatric therapeuticsPain therapeutics
Similar Companies
Other companies in Biotechnology & Life Sciences.
